The total number of records retrieved from this search are 14. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_773	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration10 MOI	In-vitro result80% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_774	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result65% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_775	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result55% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_776	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration120 MOI	In-vitro result46% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_777	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration160 MOI	In-vitro result39% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_803	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration10 MOI	In-vitro result80% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_804	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result56% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_805	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result34% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_806	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration120 MOI	In-vitro result21% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_807	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration160 MOI	In-vitro result18% cancer cell viability at 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_815	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 40 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result64% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_816	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 120 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result50% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_823	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 40 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result50% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_824	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 120 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute lymphoblastic leukemic cell line	Cell lineSUP-B15	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result38% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927